CXCR2 inverse agonism detected by arrestin redistribution.
To study CXCR2 modulated arrestin redistribution, the authors employed arrestin as a fusion protein containing either the Aequorea victoria-derived enhanced green fluorescent protein (EGFP) or a recently developed mutant of eqFP611, a red fluorescent protein derived from Entacmaea quadricolor. This mutant, referred to as RFP611, had earlier been found to assume a dimeric quarternary structure. It was therefore employed in this work as a "tandem" (td) construct for pseudo-monomeric fusion protein labeling. Both arrestin fusion proteins, containing either td-RFP611 (Arr-td-RFP611) or enhanced green fluorescent protein (EGFP; Arr-EGFP), were found to colocalize with internalized fluorescently labeled Gro-alpha a few minutes after Gro-alpha addition. Intriguingly, however, Arr-td-RFP611 and Arr-EGFP displayed distinct cellular distribution patterns in the absence of any CXCR2-activating ligand. Under these conditions, Arr-td-RFP611 showed a largely homogeneous cytosolic distribution, whereas Arr-EGFP segregated, to a large degree, into granular spots. These observations indicate a higher sensitivity of Arr EGFP to the constitutive activity of CXCR2 and, accordingly, an increased arrestin redistribution to coated pits and endocytic vesicles. In support of this interpretation, the authors found the known CXCR2 antagonist Sch527123 to act as an inverse agonist with respect to Arr-EGFP redistribution. The inverse agonistic properties of Sch527123 were confirmed in vitro in a guanine nucleotide binding assay, revealing an IC(50) value similar to that observed for Arr-EGFP redistribution. Thus, the redistribution assay, when based on Arr-EGFP, enables the profiling of antagonistic test compounds with respect to inverse agonism. When based on Arr-td-RFP611, the assay may be employed to study CXCR2 agonism or neutral antagonism.
Kredel
Simone
S
Institute of Zoology and Endocrinology, Ulm University Medical Center, Ulm, Germany.
Wolff
Michael
M
Wiedenmann
Jörg
J
Moepps
Barbara
B
Nienhaus
G Ulrich
GU
Gierschik
Peter
P
Kistler
Barbara
B
Heilker
Ralf
R
D000818:Animals; D019393:Arrestin / Q000235:genetics / Q000378:metabolism*; D001549:Benzamides / Q000494:pharmacology*; D002417:Cattle; D002460:Cell Line; D054360:Chemokine CXCL1 / Q000235:genetics / Q000378:metabolism; D003503:Cyclobutanes / Q000494:pharmacology*; D004705:Endocytosis / Q000502:physiology; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006801:Humans; D008164:Luminescent Proteins / Q000235:genetics / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D023063:Receptors, Interleukin-8B / Q000819:agonists* / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism*; D000097573:Red Fluorescent Protein
D019393:Arrestin; D001549:Benzamides; D054360:Chemokine CXCL1; D003503:Cyclobutanes; D049452:Green Fluorescent Proteins; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D008164:Luminescent Proteins; D043562:Receptors, G-Protein-Coupled; D023063:Receptors, Interleukin-8B; D011993:Recombinant Fusion Proteins; D000097573:Red Fluorescent Protein; C516686:2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide; C485184:enhanced green fluorescent protein